New laboratory methods measure a proposed ALS drug combination
Original source
Green analytical methods for quantification of a new combination therapy for amyotrophic lateral sclerosis: assessment by EPPI framework. (opens in a new tab)Compass summarised this from the study's abstract.
Study details
- Studied in
- Human
Researchers developed and validated laboratory methods to measure celecoxib and ciprofloxacin hydrochloride together in powders, prepared tablets and plasma. The methods showed reliable accuracy, precision and sensitivity, and were assessed for environmental impact and practicality. The study evaluated measurement techniques, not whether the combination treats ALS.
Why this matters
These methods could support quality control and laboratory testing of this proposed combination therapy. They do not provide evidence that celecoxib and ciprofloxacin hydrochloride improve ALS or change treatment options.
Limitations and context
This was an analytical methods study, not a clinical trial or treatment study. The combination is described as a proposed therapy, and the work does not establish its safety or effectiveness in people with ALS.